

Tina Kotek, Governor

OFFICIAL WEBSITE NOTICE


Posting Date: April 9, 2026

**OREGON HEALTH AUTHORITY DIRECTOR'S DECISION ON PHARMACY
AND THERAPEUTICS COMMITTEE RECOMMENDATIONS
DATED APRIL 6, 2026**

I have reviewed the recommendations of the Pharmacy and Therapeutics Committee set out below and have reviewed a staff memo dated April 6, 2026. Based on my review:

The recommendations of the Pharmacy and Therapeutics Committee are approved.

Recommendations with respect to the inclusion of a drug on the Oregon Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 7 days from the date this notice is posted on the website.



Sejal Hathi, MD MBA
Director

4/9/2026

Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 7 calendar days from the date of this notice. ORS 414.361(6)(b).

RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met virtually on Thursday, April 2, 2026. The Committee considered in order of priority: the safety and efficacy of the drugs being considered; the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions; and substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff ⁱ and all public comment offered,ⁱⁱ while considering the impact on people, populations and communities who have been most impacted by historic and contemporary injustices and health inequities including but not limited to Oregon Tribal Nations, American Indian or Alaska Native persons, Hispanic, Latino, Latina, or Latinx persons, Black or African American persons, Asian or Asian American persons, Pacific Islander or Native Hawaiian persons, people with disabilities, people with limited English proficiency, and immigrants and refugees, the Committee makes the following recommendations for Drug Use Review, the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), or for any other preferred drug list established by the Oregon Health Authority:

Oncology Policy Updates

The Committee recommended adding the following antineoplastic agent recently approved by the U.S. Food and Drug Administration (FDA) to Table 1 in the Oncology Agents prior authorization (PA) criteria: Rybrevant Faspro (amivantamab and hyaluronidase-lpuj).

Analgesic Class Update

The Committee recommended making no changes to the PMPDP based on a review of the clinical evidence, and to update the opioid, NSAID, and muscle relaxant PA criteria to align with current evidence for chronic pain conditions, while maintaining the ketorolac quantity limit and requiring no PA for the first two days/5 tablets of suzetrigine. After comparative cost consideration in executive session, the Committee made the following PMPDP recommendations:

DRUG	CHANGE
tizanidine 2, 4, 6 mg capsules	Make preferred on the PMPDP
piroxicam capsules	Make preferred on the PMPDP
naproxen sodium capsules	Make preferred on the PMPDP
indomethacin ER capsules	Make preferred on the PMPDP
diclofenac ER 24H tablets	Make preferred on the PMPDP
ketorolac tablets	Make preferred on the PMPDP
tramadol ER 24H tablets	Make preferred on the PMPDP
ibuprofen 300 mg tablets	Make non-preferred on the PMPDP
morphine sulfate solution	Make non-preferred on the PMPDP
hydrocodone-acetaminophen soln.	Make non-preferred on the PMPDP
codeine sulfate tablet	Make non-preferred on the PMPDP
butorphanol tartrate spray	Make non-preferred on the PMPDP
hydromorphone suppository	Make non-preferred on the PMPDP
opium-belladonna suppository	Make non-preferred on the PMPDP
lidocaine ointment	Make preferred on the PMPDP
capsaicin lotion	Make preferred on the PMPDP
lidocaine 4% solution	Make non-preferred on the PMPDP
lidocaine 4% cream	Make non-preferred on the PMPDP
hydrocortisone-pramoxine lotion	Make non-preferred on the PMPDP
hydrocortisone-pramoxine ointment	Make non-preferred on the PMPDP
hydrocortisone-pramoxine cream	Make non-preferred on the PMPDP
capsaicin 0.035% cream	Make non-preferred on the PMPDP
acetaminophen (all forms)	Make preferred on the PMPDP
aspirin-caffeine	Make preferred on the PMPDP
acetaminophen-caffeine	Make preferred on the PMPDP
aspirin/acetaminophen/caffeine	Make preferred on the PMPDP
suzetrigine	Make non-preferred on the PMPDP
all other oral pain formulations containing acetaminophen or aspirin	Make non-preferred on the PMPDP

Lynkuet (elinzanetant) New Drug Evaluation

The Committee recommended creating a “Neurokinin Receptor Antagonist” class on the PMPDP to include both fezolinetant and elinzanetant, to update the PA criteria as proposed, and designate elinzanetant non-preferred.

Hereditary Angioedema DERP Report

The Committee recommended updating the Hereditary Angioedema PA criteria as proposed to include new agents and step through preferred agents. After comparative cost consideration in executive session, the Committee recommended making generic icatibant preferred on the PMPDP.

DRUG	CHANGE
icatibant	Make preferred on the PMPDP

GNRH Agonist and Antagonist Class Update Focused on Pelvic Pain and Dysmenorrhea

The Committee recommended making no changes to the PMPDP based on a review of clinical evidence. The Committee also recommended modifying the GnRH Agonist and GnRH Antagonist PA criteria as proposed to align with HERC guidance. After comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

Waskyra (etuvetidigene autotemcel) Orphan Drug Evaluation

The Committee recommended implementing the proposed Etuvetidigene Autotemcel PA criteria.

Myalept (metreleptin) Orphan Drug Evaluation

The Committee recommended implementing the proposed Metreleptin PA criteria to ensure standard of care in patients diagnosed with lipodystrophy due to leptin deficiency.

Cephalosporins Literature Scan

The Committee recommended designating cefaclor and cefpodoxime preferred on the PMPDP based on guideline recommendations. After

comparative cost consideration in executive session the Committee made the following PMPDP recommendations:

DRUG	CHANGE
cefaclor capsules	Make preferred on the PMPDP
cefadroxil capsules	Make preferred on the PMPDP
cefpodoxime tablets	Make preferred on the PMPDP

Acne and Rosacea Class Update

The Committee recommended creating a new “Acne and Rosacea Treatments” class on the PMPDP and to designate at least one generic topical metronidazole product approved for management of rosacea preferred. The Committee recommended making brimonidine non-preferred based on clinical evidence and to maintain Twyneo (tretinoin and benzoyl peroxide) and Cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide) as non-preferred medications in the rosacea topical medication class. The Committee also recommended: make Emrosi (minocycline HCl) non-preferred in the “Oral Tetracyclines” drug class; revise the Acne PA criteria to include non-preferred topical agents for management of rosacea and add documentation of baseline assessment of disease severity; revise Oral Tetracycline PA criteria to include baseline assessments of acne and rosacea when prescribed for these indications; and add renewal criteria to both. After comparative cost consideration in executive session, the Committee recommend the following changes to the PMPDP:

DRUG	CHANGE
generic metronidazole gel & cream	Make preferred on the PMPDP
all other topical rosacea medications	Make non-preferred on the PMPDP
adapalene cream	Make non-preferred on the PMPDP
Epsolay (benzoyl peroxide) cream	Make non-preferred on the PMPDP
clindamycin phosphate foam	Make non-preferred on the PMPDP
tretinoin microspheres gel	Make non-preferred on the PMPDP

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority or their designee.

-
- ⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2026_04_02/finals/2026_04_02_PnT_Complete.pdf
ⁱⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2026_04_02/finals/2026_04_02_WrittenTestimony.pdf

